• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

New Delhi , Sept. 21

Ranbaxy Laboratories Ltd has said it has got approval to sell its generic version of Sanofi-Aventis SA's Lasix diuretic drug in the US. The drug is used to treat heart failure and renal disease.

Ranbaxy received approval from the Food and Drug Administration to sell tablets of furosemide in 20 mg, 40 mg and 80 mg dosages, the company said in a statement.

Florida-based Ranbaxy Pharmaceuticals Inc (RPI), a wholly owned subsidiary of Ranbaxy Laboratories, would sell the drug in the US.

"This approval represents an opportunity for RPI to introduce another affordable generic alternative and further increase our ever-growing product portfolio to meet the needs of our customers as well as patients in the US healthcare system. This approval is the result a strategic alliance with Ipca Laboratories Ltd of Mumbai, who will develop a number of generic prescription pharmaceutical products which will be marketed in the US by RPI in the future, following US FDA approval," Mr Jim Meehan, Vice- President, US Sales and Marketing for RPI, said in the statement.

More Stories on : Regulatory Bodies & Rulings | Pharmaceuticals | Ranbaxy Laboratories Ltd

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Fire at Tata Motors' Pune unit

Copyright © 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line